Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE
Purpose A [ 18 F]AlF-labeled somatostatin receptor (SSTR) antagonist was developed for imaging of neuroendocrine neoplasms (NENs), evaluated and compared with [ 68 Ga]Ga-DOTA-TATE. Method [ 18 F]AlF-NOTA-JR11 was synthesized manually and qualified with high-performance liquid chromatography (HPLC) a...
Gespeichert in:
Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2021-09, Vol.48 (10), p.3129-3140 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
A [
18
F]AlF-labeled somatostatin receptor (SSTR) antagonist was developed for imaging of neuroendocrine neoplasms (NENs), evaluated and compared with [
68
Ga]Ga-DOTA-TATE.
Method
[
18
F]AlF-NOTA-JR11 was synthesized manually and qualified with high-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC-MS). The cellular uptake, internalization, and saturation binding were performed with HEK293-SSTR2 cells. Biodistribution and micro-PET imaging were carried out with HEK293-SSTR2 tumor-bearing mice. [
18
F]AlF-NOTA-JR11 PET/MR imaging and [
68
Ga]Ga-DOTA-TATE PET/CT were performed with ten patients of NEN at 50~60 min post-injection (p.i.). Normal organ biodistribution and tumor detectability were evaluated.
Result
[
18
F]AlF-NOTA-JR11(24~36 GBq/μmol) was prepared within 30 min and 51.35 ± 3.30% (
n
> 10)of radiochemical yield. The radiochemical purity was 98.74 ± 1.24% (
n
> 10). Two stereoisomers were found and confirmed by LC-MS. The cellular uptake of [
18
F]AlF-NOTA-JR11 and [
68
Ga]Ga-DOTA-TATE were 4.50 ± 0.31 and 4.50 ± 0.13 %AD/10
5
cells at 30 min, and the internalization at 37 °C of [
18
F]AlF-NOTA-JR11 (5.47 ± 0.32% at 60 min) was significantly lower than [
68
Ga]Ga-DOTA-TATE (66.89 ± 1.62% at 60 min). The affinity of [
18
F]AlF-NOTA-JR11 (K
d
= 11.59 ± 1.31 nM) was slightly lower than [
68
Ga]Ga-DOTA-TATE (K
d
= 7.36 ± 1.02 nM); [
18
F]AlF-NOTA-JR11 showed high uptake in tumor (9.02 ± 0.92 %ID/g at 60 min p.i.) which can be blocked by 50 μg of NOTA-JR11 (3.40 ± 1.64 %ID/g at 60 min p.i.); the result was coincident with micro-PET imaging. Imaging study of NEN patients showed that more lesions were found only by [
18
F]AlF-NOTA-JR11 (
n
= 67 vs. 1 only by [
68
Ga]Ga-DOTA-TATE), and the uptakes of [
18
F]AlF-NOTA-JR11 in majority normal organs were significantly lower than [
68
Ga]Ga-DOTA-TATE. The target to nontarget of maximum of standard uptake value (SUVmax) of [
18
F]AlF-NOTA-JR11 in liver lesions were significantly higher than those of [
68
Ga]Ga-DOTA-TATE.
Conclusion
Qualitied [
18
F]AlF-NOTA-JR11 is prepared conveniently with reasonable yield, and it can bind SSTR2 specifically with high affinity. Excellent imaging capability of [
18
F]AlF-NOTA-JR11 for NENs is superior to [
68
Ga]Ga-DOTA-TATE, especially in digestive system. It has a great potential for imaging of NENs. |
---|---|
ISSN: | 1619-7070 1619-7089 |
DOI: | 10.1007/s00259-021-05249-8 |